These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 17045989)

  • 1. Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease.
    Scheller D; Chan P; Li Q; Wu T; Zhang R; Guan L; Ravenscroft P; Guigoni C; Crossman AR; Hill M; Bezard E
    Exp Neurol; 2007 Feb; 203(2):415-22. PubMed ID: 17045989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pinhole SPECT imaging of dopamine transporters correlates with dopamine transporter immunohistochemical analysis in the MPTP mouse model of Parkinson's disease.
    Andringa G; Drukarch B; Bol JG; de Bruin K; Sorman K; Habraken JB; Booij J
    Neuroimage; 2005 Jul; 26(4):1150-8. PubMed ID: 15908232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Striatal Dopamine Transporter Modulation After Rotigotine: Results From a Pilot Single-Photon Emission Computed Tomography Study in a Group of Early Stage Parkinson Disease Patients.
    Rossi C; Genovesi D; Marzullo P; Giorgetti A; Filidei E; Corsini GU; Bonuccelli U; Ceravolo R
    Clin Neuropharmacol; 2017; 40(1):34-36. PubMed ID: 27941527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor.
    Joyce JN; Woolsey C; Ryoo H; Borwege S; Hagner D
    BMC Biol; 2004 Oct; 2():22. PubMed ID: 15473914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine transporter binding is unaffected by L-DOPA administration in normal and MPTP-treated monkeys.
    Fernagut PO; Li Q; Dovero S; Chan P; Wu T; Ravenscroft P; Hill M; Chen Z; Bezard E
    PLoS One; 2010 Nov; 5(11):e14053. PubMed ID: 21124922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single photon emission computer tomography of dopamine transporters in monkeys and humans with 99mTc-TRODAT-1.
    Hu P; Chen L; Zhang HQ; Li JR; Liang H
    Chin Med J (Engl); 2004 Jul; 117(7):1056-9. PubMed ID: 15265382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SPECT imaging of dopamine transporter sites in normal and MPTP-Treated rhesus monkeys.
    Fischman AJ; Babich JW; Elmaleh DR; Barrow SA; Meltzer P; Hanson RN; Madras BK
    J Nucl Med; 1997 Jan; 38(1):144-50. PubMed ID: 8998169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine transporter loss and clinical changes in MPTP-lesioned primates.
    Eberling JL; Bankiewicz KS; Pivirotto P; Bringas J; Chen K; Nowotnik DP; Steiner JP; Budinger TF; Jagust WJ
    Brain Res; 1999 Jun; 832(1-2):184-7. PubMed ID: 10375668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurotensin receptors and dopamine transporters: effects of MPTP lesioning and chronic dopaminergic treatments in monkeys.
    Goulet M; Morissette M; Grondin R; Falardeau P; Bédard PJ; Rostène W; Di Paolo T
    Synapse; 1999 Jun; 32(3):153-64. PubMed ID: 10340626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trihexyphenidyl interactions with the dopamine D1-selective receptor agonist SKF-82958 and the D2-selective receptor agonist N-0923 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced hemiparkinsonian monkeys.
    Domino EF; Ni L
    J Pharmacol Exp Ther; 1998 Jan; 284(1):307-11. PubMed ID: 9435192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rotigotine: transdermal dopamine agonist treatment of Parkinson's disease and restless legs syndrome.
    Splinter MY
    Ann Pharmacother; 2007 Feb; 41(2):285-95. PubMed ID: 17213296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma levels of rotigotine and the reversal of motor deficits in MPTP-treated primates.
    Rose S; Scheller DK; Breidenbach A; Smith L; Jackson M; Stockwell K; Jenner P
    Behav Pharmacol; 2007 Mar; 18(2):155-60. PubMed ID: 17351422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroprotective effects of rotigotine in the acute MPTP-lesioned mouse model of Parkinson's disease.
    Scheller D; Stichel-Gunkel C; Lübbert H; Porras G; Ravenscroft P; Hill M; Bezard E
    Neurosci Lett; 2008 Feb; 432(1):30-4. PubMed ID: 18162314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys.
    Yoshimura N; Mizuta E; Yoshida O; Kuno S
    J Pharmacol Exp Ther; 1998 Jul; 286(1):228-33. PubMed ID: 9655864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
    Johnston TH; Fox SH; McIldowie MJ; Piggott MJ; Brotchie JM
    J Pharmacol Exp Ther; 2010 Jun; 333(3):865-73. PubMed ID: 20231306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using striatal dopamine transporter single photon emission computed tomography imaging to rule out Dementia with Lewy Bodies in elderly patients with antipsychotic-induced parkinsonism.
    Schuster JP; Buhl C; Archambaud F; Hardy P; Chouinard G; Prigent A; Corruble E
    Psychiatry Clin Neurosci; 2007 Apr; 61(2):206. PubMed ID: 17362445
    [No Abstract]   [Full Text] [Related]  

  • 17. The 5α-reductase inhibitor Dutasteride but not Finasteride protects dopamine neurons in the MPTP mouse model of Parkinson's disease.
    Litim N; Bourque M; Al Sweidi S; Morissette M; Di Paolo T
    Neuropharmacology; 2015 Oct; 97():86-94. PubMed ID: 26006269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rotigotine: Parkinson's disease: a step backward.
    Prescrire Int; 2008 Apr; 17(94):60. PubMed ID: 18516813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study on retinal dopamine transporter in form deprivation myopia using the radiopharmaceutical tracer 99mTc-TRODAT-1.
    Zhao J; Qu X; Qi Y; Zhou W; Liu X
    Nucl Med Commun; 2010 Oct; 31(10):910-5. PubMed ID: 20700065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of alpha-dihydroergocryptine and levodopa monotherapy in Parkinson's disease: assessment of changes in DAT binding with [123I]IPT SPECT.
    Pöpperl G; Tatsch K; Ruzicka E; Storch A; Gasser T; Schwarz J
    J Neural Transm (Vienna); 2004 Aug; 111(8):1041-52. PubMed ID: 15254792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.